Fintel reports that on June 16, 2025, Leerink Partners initiated coverage of Boston Scientific (NYSE:BSX) with a Outperform recommendation.

Analyst Price Forecast Suggests 19.99% Upside

As of June 2, 2025, the average one-year price target for Boston Scientific is $119.67/share. The forecasts range from a low of $90.90 to a high of $136.50. The average price target represents an increase of 19.99% from its latest reported closing price of $99.74 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Boston Scientific is 14,925MM, a decrease of 14.98%. The projected annual non-GAAP EPS is 2.45.

What is the Fund Sentiment?

There are 2,774 funds or institutions reporting positions in Boston Scientific. This is an increase of 179 owner(s) or 6.90% in the last quarter. Average portfolio weight of all funds dedicated to BSX is 0.57%, an increase of 7.86%. Total shares owned by institutions decreased in the last three months by 0.51% to 1,531,909K shares. The put/call ratio of BSX is 0.90, indicating a bullish outlook.

What are Other Shareholders Doing?

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 46,630K shares representing 3.15% ownership of the company. In its prior filing, the firm reported owning 46,143K shares , representing an increase of 1.04%. The firm increased its portfolio allocation in BSX by 19.06% over the last quarter.

VFINX - Vanguard 500 Index Fund Investor Shares holds 40,952K shares representing 2.77% ownership of the company. In its prior filing, the firm reported owning 39,895K shares , representing an increase of 2.58%. The firm increased its portfolio allocation in BSX by 18.38% over the last quarter.

Primecap Management holds 36,497K shares representing 2.47% ownership of the company. In its prior filing, the firm reported owning 36,930K shares , representing a decrease of 1.19%. The firm increased its portfolio allocation in BSX by 19.15% over the last quarter.

Wellington Management Group Llp holds 33,198K shares representing 2.24% ownership of the company. In its prior filing, the firm reported owning 36,165K shares , representing a decrease of 8.94%. The firm decreased its portfolio allocation in BSX by 84.86% over the last quarter.

Geode Capital Management holds 31,802K shares representing 2.15% ownership of the company. In its prior filing, the firm reported owning 30,626K shares , representing an increase of 3.70%. The firm decreased its portfolio allocation in BSX by 37.12% over the last quarter.

Boston Scientific Background Information
(This description is provided by the company.)

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, The company advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.